Skip to main content
. 2022 Sep 27;29(3):513–520. doi: 10.1158/1078-0432.CCR-21-1258

Figure 2.

Figure 2. Forest plots of overall survival and progression-free survival according to underlying liver disease etiology. Data are shown from phase III trials testing immunotherapies in patients with advanced HCC.

Forest plots of overall survival and progression-free survival according to underlying liver disease etiology. Data are shown from phase III trials testing immunotherapies in patients with advanced HCC.